Meta description: A regulatory update on the Supira System trial in complex high risk PCI under way at Supira Medical, focusing on safety and performance signals. Publication date context: February 13, 2026. In regulatory news terms the study titled Study of the Supira System in Patients With Complex High Risk Percutaneous Coronary Intervention is listed on ClinicalTrials.gov with the identifier NCT07407816 and is described as recruiting. The study targets patients with heart disease, coronary arterial disease and heart failure who will receive the Supira System device as part of a percutaneous intervention. Supira Medical serves as sponsor and is overseeing the trial with the aim to gather data on device safety and performance in a high risk setting. This registration aligns with regulatory expectations for device safety monitoring and early signal detection in complex procedures. Below is a concise briefing on what changed, who is affected, how safety and performance will be evaluated and what the implications are for regulatory practice.
What changed for the Supira System in complex high risk PCI?
The ClinicalTrials.gov entry NCT07407816 confirms a study of the Supira System in patients with complex high risk PCI. The conditions listed include heart disease, coronary arterial disease and heart failure. Recruiting is noted in the record. The sponsor is Supira Medical, which positions the device within a regulatory framework that requires safety and performance data. Readers should understand that no efficacy claims are made at this stage. Data collection will focus on safety events, device integration and procedural workflow during complex PCI. This update reflects a broader regulatory emphasis on structured safety data for devices used in high risk procedures. The study may also illuminate how the Supira System integrates with existing interventional workflows and whether device related complications occur in real world settings. The information is intended to guide clinicians and regulatory staff as they assess risk management plans and potential indications for use.
Who is affected by this trial?
The trial targets patients with heart disease and related conditions who undergo complex high risk PCI. The recruiting status indicates ongoing feasibility and potential enrollment. Clinicians planning complex PCI should monitor the study to understand how the Supira System is intended to be used in high risk settings. The record confirms an industry sponsor, and the device trial emphasizes safety and performance data capture across diverse patient scenarios. Hospitals and operators evaluating new devices for high risk PCI may use this information to inform risk assessment, training needs and procedural planning. The absence of efficacy claims at this stage keeps the emphasis on safety, device handling and patient care processes in demanding procedures.
How will the Supira System be evaluated for safety and performance?
The trial is designed to generate safety data and assess device performance in a high risk context. The approach follows regulatory expectations for device surveillance during complex interventional procedures. No explicit efficacy outcomes are claimed in the current record, and results will be interpreted within the context of a safety and performance evidence package. Regulators will review trial design and progress as part of ongoing monitoring of new device use in high risk PCI. The study may help identify adverse event patterns, device integration issues and operator training needs, all of which influence future labeling decisions and risk mitigation strategies.
What are the regulatory implications for a complex high risk PCI device study?
Data from this study may inform future labeling or post market surveillance strategies for the Supira System. The trial aligns with MDR Annex XIV expectations to provide evidence on safety and performance in high risk procedures. The notice underscores the need for ongoing safety assessment and transparent reporting from the sponsor. For stakeholders in clinical and regulatory roles the update signals a continuing emphasis on data driven decision making and risk management in device deployment. See the ClinicalTrials.gov listing for official details and status. See Internal post 1 at /regulatory-affairs-insights and Internal post 2 at /device-safety-monitoring. The combination of sponsor driven data and publicly accessible trial records reflects current regulatory practice that favors proactive risk management and post market learning.
FAQ
- What is the Supira System trial about? The study is a safety and performance evaluation in patients undergoing complex high risk PCI.
- Who sponsors the study? Supira Medical is listed as sponsor.
- Where can readers find the official trial record? The ClinicalTrials.gov listing is NCT07407816 and can be accessed at https://clinicaltrials.gov/study/NCT07407816?term=medical+device.
- Which conditions are described? Heart disease, coronary arterial disease and heart failure.
- What is the recruitment status? Recruiting.
Conclusion
The Supira System study in complex high risk PCI represents a structured step in gathering safety and performance data for a device intended to support high risk procedures. For clinicians this means staying aware of the evolving safety profile and usage guidance as evidence accrues. For regulators the ongoing data collection supports post market surveillance and decision making about labeling and indications as appropriate. Stakeholders should monitor the ClinicalTrials.gov listing for updates, results and any amendments to study design.
Disclaimer
This article is for professional audiences and does not constitute legal advice. It summarizes publicly available regulatory information and does not interpret legal requirements beyond what is stated by the source.
https://clinicaltrials.gov/study/NCT07407816?term=medical+device